Neoplasm Staging

• 

  Subject Areas on Research

  • "Thin" malignant melanoma: risk factors and clinical management. 
  • (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 
  • (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes. 
  • (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 
  • 18F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial. 
  • 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. 
  • 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. 
  • 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. 
  • A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. 
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 
  • A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial. 
  • A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. 
  • A Minimally Invasive Approach to Lobectomy After Induction Therapy Does Not Compromise Survival. 
  • A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. 
  • A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. 
  • A National Analysis of Minimally Invasive Vs Open Segmentectomy for Stage IA Non-Small-Cell Lung Cancer. 
  • A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Clinical Stage II Non-Small-Cell Lung Cancer. 
  • A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. 
  • A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. 
  • A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. 
  • A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. 
  • A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. 
  • A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 
  • A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients. 
  • A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. 
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. 
  • A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiated-Type Intramucosal Gastric Cancer. 
  • A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer. 
  • A Risk-prediction Model Based on Lymph-node Metastasis for Incorporation Into a Treatment Algorithm for Signet Ring Cell-type Intramucosal Gastric Cancer. 
  • A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. 
  • A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. 
  • A branching process model of ovarian cancer. 
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. 
  • A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate. 
  • A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. 
  • A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. 
  • A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. 
  • A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience. 
  • A comparison of two visual inspection methods for cervical cancer screening among HIV-infected women in Kenya. 
  • A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. 
  • A functional variant of tandem repeats in human telomerase gene was associated with survival of patients with early stages of non-small cell lung cancer. 
  • A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. 
  • A model for morbidity after lung resection in octogenarians. 
  • A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). 
  • A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. 
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. 
  • A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. 
  • A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. 
  • A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. 
  • A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. 
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. 
  • A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. 
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. 
  • A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. 
  • A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). 
  • A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. 
  • A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. 
  • A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. 
  • A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. 
  • A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. 
  • A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). 
  • A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. 
  • A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery. 
  • A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. 
  • A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. 
  • A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. 
  • A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. 
  • A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. 
  • A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. 
  • A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. 
  • A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. 
  • A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. 
  • A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial. 
  • A retrospective cohort study of comprehensive peripheral and deep margin assessment in Merkel cell carcinoma: Standard margins may be unreliable. 
  • A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. 
  • A review of chemotherapy trials for malignant mesothelioma. 
  • A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. 
  • A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 
  • A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. 
  • A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. 
  • A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. 
  • A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. 
  • A targeted genetic association study of epithelial ovarian cancer susceptibility. 
  • A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. 
  • A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. 
  • ACR Appropriateness Criteria Renal Cell Carcinoma Staging. 
  • ACR Appropriateness Criteria Staging of Testicular Malignancy. 
  • ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. 
  • ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer. 
  • ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. 
  • ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. 
  • ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer. 
  • ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. 
  • ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. 
  • ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. 
  • ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. 
  • AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization. 
  • ASO Author Reflections: Molecular Signatures May Render Surgical Staging of the Axilla Obsolete. 
  • ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. 
  • Abdominal magnetic resonance imaging at 3 T: oncological applications. 
  • Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. 
  • Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. 
  • Absence of a relationship of size of primary colon carcinoma with metastasis and survival. 
  • Absence of correlation between nuclear morphometry and survival in stage I non-small cell lung carcinoma. 
  • Accuracy in staging of renal cell carcinoma involving vena cava. 
  • Accuracy of real time noninvasive temperature measurements using magnetic resonance thermal imaging in patients treated for high grade extremity soft tissue sarcomas. 
  • Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. 
  • Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. 
  • Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma. 
  • Acral melanoma: a review of 185 patients with identification of prognostic variables. 
  • Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. 
  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. 
  • Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. 
  • Adenocarcinoma of the prostate. Part II: Tissue prognosticators. 
  • Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. 
  • Adenocarcinoma of the prostate: stage A1. 
  • Adenocarcinoma of the stomach. Changing patterns over the last 4 decades. 
  • Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. 
  • Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. 
  • Adequacy of Lymph Node Yield for Papillary Thyroid Cancer: An Analysis of 23,131 Patients. 
  • Adequacy of distal resection margin following preoperative combined modality therapy for rectal cancer. 
  • Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. 
  • Adherence to quality indicators and survival in patients with breast cancer. 
  • Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response. 
  • Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. 
  • Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. 
  • Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy. 
  • Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer. 
  • Adjuvant chemotherapy after surgery and radiation for stage III and IV head and neck cancer. 
  • Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. 
  • Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit. 
  • Adjuvant chemotherapy in older women with early-stage breast cancer. 
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. 
  • Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant postoperative radiation therapy for colonic carcinoma. 
  • Adjuvant postoperative radiation therapy for rectal adenocarcinoma. 
  • Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma. 
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adjuvant therapy for pancreatic cancer: current status and future directions. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. 
  • Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer. 
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. 
  • Adrenal Imaging Features Predict Malignancy Better than Tumor Size. 
  • Advanced stage primary mucinous ovarian carcinoma. Where do we stand ? 
  • Advances in the management of conjunctival melanoma. 
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 
  • Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. 
  • Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. 
  • African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. 
  • African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. 
  • After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. 
  • After surgery for stage II or III colorectal cancer, more vs less frequent follow-up did not differ for 5-year mortality. 
  • Age as a prognostic factor in the malignant melanoma population. 
  • Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. 
  • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 
  • Allele loss on chromosome 1p36 in epithelial ovarian cancers. 
  • Allergies, obesity, other risk factors and survival from pancreatic cancer. 
  • Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. 
  • Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. 
  • American College of Radiology Appropriateness Criteria(®) treatment of stage I T1 glottic cancer. 
  • American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. 
  • American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. 
  • An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients. 
  • An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. 
  • An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. 
  • An exploration of relative health stock in advanced cancer patients. 
  • An integrated molecular profile of endometrioid ovarian cancer. 
  • An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). 
  • Anal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Anal cancer: an overview. 
  • Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. 
  • Anal neoplasms. 
  • Analgesic and antiemetic needs following minimally invasive vs open staging for endometrial cancer. 
  • Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. 
  • Analysis of T-cell subsets in B-cell chronic lymphocytic leukemia: a correlation with the stage of disease. 
  • Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. 
  • Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. 
  • Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. 
  • Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Analysis of recurrence, complications, and functional results with free jejunal flaps. 
  • Analysis of results of radiation therapy for Stage II carcinoma of the cervix. 
  • Analysis of results of radiation therapy for stage IB carcinoma of the cervix. 
  • Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. 
  • Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. 
  • Anatomy and Breast Cancer Staging: Is It Still Relevant? 
  • Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. 
  • Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. 
  • Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. 
  • Angiomirs expression profiling in diffuse large B-Cell lymphoma. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. 
  • Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics. 
  • Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. 
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. 
  • Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. 
  • Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. 
  • Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. 
  • Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? 
  • Are there patients with stage I rectal carcinoma at risk for failure after abdominoperineal resection? 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Artificial neural networks improve the accuracy of cancer survival prediction. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? 
  • Assessment of Treatment Response With Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI in Patients With Early-Stage Breast Cancer Treated With Single-Dose Preoperative Radiotherapy: Initial Results. 
  • Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and the relevance of spiritual well-being--a Hoosier Oncology Group Study. 
  • Association Between Age and Nodal Metastasis in Papillary Thyroid Carcinoma. 
  • Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer. 
  • Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). 
  • Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. 
  • Association between environmental quality and prostate cancer stage at diagnosis. 
  • Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Association between ratio of matrix metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. 
  • Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. 
  • Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. 
  • Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. 
  • Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. 
  • Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. 
  • Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. 
  • Association of Life-Course Educational Attainment and Breast Cancer Grade in the MEND Study. 
  • Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype. 
  • Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults. 
  • Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. 
  • Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. 
  • Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). 
  • Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. 
  • Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. 
  • Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. 
  • Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. 
  • Automating Treatment Summary Development Using Electronic Billing Information: A Pilot Study of Survivors of Head and Neck Cancer. 
  • Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough? 
  • Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. 
  • Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. 
  • Bayesian inference for the stereotype regression model: Application to a case-control study of prostate cancer. 
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. 
  • Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia. 
  • Bilateral pelvic lymph node metastases in a case of FIGO stage IA(1) adenocarcinoma of the cervix. 
  • Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. 
  • Biologic hazards of double primary neoplasms among patients with genitourinary malignancy. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. 
  • Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Bladder cancer. Clinical guidelines in oncology. 
  • Bladder cancer. Clinical practice guidelines in oncology. 
  • Bladder cancer: race differences in extent of disease at diagnosis. 
  • Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. 
  • Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • Bone cancer clinical practice guidelines. 
  • Bone cancer. 
  • Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women. 
  • Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. 
  • Breast Cancer Version 2.2015. 
  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. 
  • Breast cancer in women under 35 years of age. 
  • Breast cancer in young women: Imaging and clinical course. 
  • Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. 
  • Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview. 
  • Breast cancer survival in African-American women by hormone receptor subtypes. 
  • Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. 
  • Breast cancer, version 3.2013: featured updates to the NCCN guidelines. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Breast cancer: noninvasive and special situations. 
  • Breast conservation surgery using nipple-areolar resection for central breast cancers. 
  • Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. 
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods a Southwest Oncology Group study. 
  • CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA. 
  • CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer. 
  • CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma. 
  • CT mucosal window settings: a novel approach to evaluating early T-stage head and neck carcinoma. 
  • CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. 
  • Cabozantinib in genitourinary malignancies. 
  • Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features? 
  • Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? 
  • Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? 
  • Can pretreatment computed tomography findings predict local control in T3 squamous cell carcinoma of the glottic larynx treated with radiotherapy alone? 
  • Cancer Outcomes in DCIS Patients Without Locoregional Treatment. 
  • Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Cancer and pregnancy: the clinician's perspective. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. 
  • Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Carcinoma of the cervix, stage III. Results of radiation therapy. 
  • Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys. 
  • Carcinoma of the prostate: the therapeutic dilemma. 
  • Carcinoma of the tonsillar region: a multivariate analysis of 243 patients treated with radical radiotherapy. 
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. 
  • Carcinoma of the urethra: radiation oncology. 
  • Caregiver-guided pain coping skills training for patients with advanced cancer: Background, design, and challenges for the CaringPals study. 
  • Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. 
  • Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum. 
  • Caspase-8 levels correlate with the expression of signal transducer and activator of transcription 1 in high-grade but not lower grade neuroblastoma. 
  • Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. 
  • Causal effects of time-dependent treatments in older patients with non-small cell lung cancer. 
  • Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. 
  • Central nervous system cancers: Clinical Practice Guidelines in Oncology. 
  • Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. 
  • Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Cervical cancer. 
  • Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. 
  • Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual. 
  • Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival. 
  • Changes in tumor proliferation of rectal cancer induced by preoperative 5-fluorouracil and irradiation. 
  • Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. 
  • Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. 
  • Characteristics of cancer diagnoses and staging in South Western Victoria: a rural perspective. 
  • Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. 
  • Characterization of sporadic colon cancer by patterns of genomic instability. 
  • Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. 
  • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. 
  • Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. 
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 
  • Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. 
  • Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. 
  • Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. 
  • Chemotherapy and radiation of anal canal cancer: the first approach. 
  • Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. 
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic lymphocytic leukemia. 
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. 
  • Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. 
  • Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. 
  • Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. 
  • Circulating tumor cells in melanoma patients. 
  • Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. 
  • Classification and treatment of plantar fibromatosis. 
  • Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. 
  • Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. 
  • Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. 
  • Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. 
  • Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. 
  • Clinical and pathological stage discordance among 433,514 breast cancer patients. 
  • Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. 
  • Clinical application of a 3D ultrasound-guided prostate biopsy system. 
  • Clinical applications of PET in oncology. 
  • Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 
  • Clinical correlation of previously undetected cancer-related incidental findings on CT planning scans for radiation therapy. 
  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. 
  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 
  • Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. 
  • Clinical features and outcome of primary pancreatic lymphoma. 
  • Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. 
  • Clinical presentation and outcome of retinoblastoma based on age at presentation: a review of 1450 children. 
  • Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. 
  • Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical staging of prostate cancer: reproducibility and clarification of issues. 
  • Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. 
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. 
  • Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Clinical, pathologic, and functional outcomes after nephron-sparing surgery in patients with a solitary kidney: a multicenter experience. 
  • Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. 
  • Clinicopathological characteristics of surgically treated localized renal masses in patients previously exposed to chemotherapy. 
  • Clinicopathological features to distinguish malignant solitary fibrous tumors of the prostate from prostatic stromal tumors. 
  • Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. 
  • Co-expression of urokinase with haptoglobin in human carcinomas. 
  • Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). 
  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Colon sentinel lymph node mapping: practical surgical applications. 
  • Colonoscopic indirect lymphangiography in a canine model. 
  • Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. 
  • Colorectal cancer pelvic recurrences: determinants of resectability. 
  • Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. 
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. 
  • Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. 
  • Combined modality therapy for rectal and colon cancer. 
  • Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. 
  • Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. 
  • Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks. 
  • Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. 
  • Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. 
  • Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. 
  • Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. 
  • Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results. 
  • Common and Co-Occurring Symptoms Experienced by Patients With Gastric Cancer. 
  • Comorbidity burden and guideline-concordant care for breast cancer. 
  • Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. 
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 
  • Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. 
  • Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. 
  • Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. 
  • Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. 
  • Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. 
  • Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. 
  • Comparison of plain radiography, conventional tomography, and computed tomography in detecting intrathoracic lymph node metastases from lung carcinoma. 
  • Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. 
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. 
  • Comparison of survival of stage I-III colon cancer by travel distance and hospital volume. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. 
  • Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. 
  • Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. 
  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. 
  • Complications of therapy for testicular cancer. 
  • Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. 
  • Comprehensive handbook for developing a bladder cancer cystectomy database. 
  • Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. 
  • Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. 
  • Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation. 
  • Computed tomography in the detection of abdominal metastases from malignant melanoma. 
  • Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. 
  • Concordance of histopathologic and cytologic grading in musculoskeletal sarcomas: can grades obtained from analysis of the fine-needle aspirates serve as the basis for therapeutic decisions? 
  • Concordant, non-atypical breast papillomas do not require surgical excision: A 10-year multi-institution study and review of the literature. 
  • Concurrent Definitive Immunoradiotherapy for Patients with Stage III-IV Head and Neck Cancer and Cisplatin Contraindication. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. 
  • Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer. 
  • Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. 
  • Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. 
  • Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. 
  • Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 
  • Consensus-based standards for best supportive care in clinical trials in advanced cancer. 
  • Considerations of psychosocial illness phase in cancer survival. 
  • Contemporary Approaches to In-Transit Melanoma. 
  • Contemporary hormonal management of advanced prostate cancer. 
  • Contemporary surgical options for metastatic colorectal cancer. 
  • Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. 
  • Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer? 
  • Contribution of chemotherapy to improved prognosis in stage 4 gastric cancer: trend analysis of a regional population-based cancer registry in Japan. 
  • Controversies regarding laparoscopic colectomy for malignant diseases. 
  • Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. 
  • Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. 
  • Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. 
  • Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery. 
  • Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. 
  • Cost comparison of radical retropubic and radical perineal prostatectomy: single institution experience. 
  • Cost effectiveness of a test to detect metastases for endometrial cancer. 
  • Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 
  • Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. 
  • Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. 
  • Cost-effectiveness of treatment of early stage endometrial cancer. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Critical Assessment of Clinical Prognostic Tools in Melanoma. 
  • Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. 
  • Current and future cancer staging after neoadjuvant treatment for solid tumors. 
  • Current state of sentinel lymph nodes for women with endometrial cancer. 
  • Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. 
  • Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. 
  • Cyclin E overexpression relates to ovarian cancer histology but not to risk factors. 
  • Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. 
  • DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. 
  • DNA in radical prostatectomy specimens. Prognostic value of tumor ploidy. 
  • DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions. 
  • Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma. 
  • Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation? 
  • Dataset for the reporting of carcinoma of the esophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. 
  • De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer. 
  • De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. 
  • Debulking nephrectomy in metastatic renal cancer. 
  • Decreased E-cadherin expression correlates with higher stage of Wilms' tumors. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Defining surgical indications for type I gastric carcinoid tumor. 
  • Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. 
  • Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. 
  • Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. 
  • Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. 
  • Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. 
  • Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer. 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. 
  • Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. 
  • Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique. 
  • Detecting colorectal cancer in stool with the use of multiple genetic targets. 
  • Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). 
  • Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. 
  • Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. 
  • Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? 
  • Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer. 
  • Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. 
  • Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Development of a multimarker assay for early detection of ovarian cancer. 
  • Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. 
  • Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. 
  • Diagnostic protein discovery using proteolytic peptide targeting and identification. 
  • Diagnostic thoracic-computed tomography in radiotherapy for loco-regional recurrent breast carcinoma. 
  • Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). 
  • Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. 
  • Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Differences between black and white patients with cancer of the uterine corpus in interval from symptom recognition to initial medical consultation (United States). 
  • Differences in imaging characteristics of HPV-positive and HPV-Negative oropharyngeal cancers: a blinded matched-pair analysis. 
  • Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. 
  • Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. 
  • Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. 
  • Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. 
  • Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Discussion. 
  • Discussion. 
  • Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. 
  • Disparities in breast carcinoma treatment in Asian/Pacific Islander women. A challenge to the provider. 
  • Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. 
  • Distal margin requirements after preoperative chemoradiotherapy for distal rectal carcinomas: are < or = 1 cm distal margins sufficient? 
  • Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. 
  • Distress and motivation for smoking cessation among lung cancer patients' relatives who smoke. 
  • Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected? 
  • Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma. 
  • Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. 
  • Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? 
  • Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). 
  • Do overall treatment time, field size, and treatment energy influence local control of T1-T2 squamous cell carcinomas of the glottic larynx? 
  • Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance? 
  • Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone? 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does Angiosarcoma of the Breast Need Nodal Staging? 
  • Does Fragmentation of Care in Locally Advanced Rectal Cancer Increase Patient Mortality? 
  • Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. 
  • Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. 
  • Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? 
  • Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? 
  • Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer? 
  • Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Does vocal cord fixation preclude nonsurgical management of laryngeal cancer? 
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 
  • Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. 
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. 
  • Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 
  • Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. 
  • Dual energy MDCT assessment of renal lesions: an overview. 
  • Ductal carcinoma in situ in BRCA mutation carriers. 
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
  • Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. 
  • Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. 
  • Dysphagia prevalence and associated survival differences in older patients with lung cancer: A SEER-Medicare population-based study. 
  • E-cadherin in gastric carcinomas: Relations with histological parameters and its prognostic value. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. 
  • EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). 
  • Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center. 
  • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. 
  • Early detection of lung cancer in a population at high risk due to occupation and smoking. 
  • Early onset pancreatic malignancies: Clinical characteristics and survival associations. 
  • Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. 
  • Early-stage melanoma and hematopoietic stem cell transplantation outcomes. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Ectopic expression of mucins in colorectal cancer metastasis. 
  • Editorial comment. 
  • Editorial comment. 
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. 
  • Effect of Lymph Node Assessment on Outcomes in Surgery for Limited Stage Small Cell Lung Cancer. 
  • Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. 
  • Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. 
  • Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. 
  • Effect of health care delivery models on melanoma thickness and stage in a university-based referral center: an observational pilot study. 
  • Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. 
  • Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma. 
  • Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. 
  • Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. 
  • Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage. 
  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. 
  • Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. 
  • Efficacy of radiographic chest imaging in patients with testicular cancer. 
  • Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study. 
  • Elevation of multiple serum markers in patients with stage I ovarian cancer. 
  • Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction. 
  • Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. 
  • Endocrine therapy in early-stage breast cancer care: defining the appropriate regimen and time frame. 
  • Endoscopic approaches for early-stage esophageal cancer: current options. 
  • Endoscopic ultrasonography in the diagnosis and staging of neoplasms of the head and neck. 
  • Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma. 
  • Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Enhancer-derived long non-coding RNAs CCAT1 and CCAT2 at rs6983267 has limited predictability for early stage colorectal carcinoma metastasis. 
  • Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. 
  • Epidermal growth factor receptor expression in normal and malignant endometrium. 
  • Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. 
  • Epigenetic determinants of ovarian clear cell carcinoma biology. 
  • Equivalent Survival Between Lobectomy and Segmentectomy for Clinical Stage IA Lung Cancer. 
  • Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals. 
  • Erectile function outcome reporting after clinically localized prostate cancer treatment. 
  • Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Esophageal and esophagogastric junction cancers. 
  • Esophageal cancer. 
  • Esophageal cancer. Clinical practice guidelines in oncology. 
  • Esophageal-subarachnoid fistula: a case of spontaneous tension pneumocephalus in the setting of esophageal cancer. 
  • Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. 
  • Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: calculations from clinical trials. 
  • Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. 
  • Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 
  • Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. 
  • Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. 
  • Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? 
  • Evaluation of an RNAseq-Based Immunogenomic Liquid Biopsy Approach in Early-Stage Prostate Cancer. 
  • Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. 
  • Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. 
  • Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. 
  • Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. 
  • Evaluation of prognostic factors and staging in gestational trophoblastic tumor. 
  • Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. 
  • Evaluation of the Axillary Surgery Performed in Clinically Node-Positive Breast Cancer Patients Following Neoadjuvant Chemotherapy. 
  • Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. 
  • Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. 
  • Evaluation of two management strategies for preoperative grade 1 endometrial cancer. 
  • Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. 
  • Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. 
  • Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. 
  • Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 
  • Evolving role of FDG PET/CT in multiple myeloma imaging and management. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Examining potential colorectal cancer care disparities in the Veterans Affairs health care system. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Expert pathology review and endoscopic mucosal resection alters the diagnosis of patients referred to undergo therapy for Barrett's esophagus. 
  • Exploration of Exercise Outcome Expectations Among Breast Cancer Survivors. 
  • Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Expression of P120 catenin, Kaiso, and metastasis tumor antigen-2 in thymomas. 
  • Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • Expression signatures of TP53 mutations in serous ovarian cancers. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Extended surgical staging for potentially resectable malignant pleural mesothelioma. 
  • Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. 
  • Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer. Reply. 
  • Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. 
  • External beam radiation followed by planned neck dissection and brachytherapy for base of tongue squamous cell carcinoma. 
  • External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. 
  • FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. 
  • FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 
  • FDG PET/CT in the management of colorectal and anal cancers. 
  • FDG PET/CT in the management of nasopharyngeal carcinoma. 
  • FDG PET/CT in the management of primary pleural tumors and pleural metastases. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. 
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. 
  • Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. 
  • Factors affecting outcome in locally advanced breast cancer. 
  • Factors associated with survival in pediatric adrenocortical carcinoma: An analysis of the National Cancer Data Base (NCDB). 
  • Factors associated with time to surgery in melanoma: An analysis of the National Cancer Database. 
  • Factors impacting survival in children with renal cell carcinoma. 
  • Factors predicting prostatic biopsy Gleason sum under grading. 
  • Failure patterns following curative resection of colonic carcinoma. 
  • False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. 
  • Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. 
  • Feasibility of hybrid thoracoscopic lobectomy and en-bloc chest wall resection. 
  • Fewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer. 
  • Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). 
  • Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. 
  • Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Findings on Surveillance Imaging After Preoperative Partial Breast Irradiation for Early Stage Breast Cancer. 
  • Fine-tuning robot-assisted radical prostatectomy planning with MRI. 
  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. 
  • First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. 
  • Five hundred patients with Merkel cell carcinoma evaluated at a single institution. 
  • Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. 
  • Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. 
  • Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma: does ploidy status enhance prognostic stratification over stage alone? 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. 
  • Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Focal therapy for prostate cancer. 
  • Focal therapy for prostate cancer: possibilities and limitations. 
  • Focal therapy of prostate and kidney cancer. 
  • Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. 
  • Frequency and prognostic significance of preoperatively detected enlarged regional lymph nodes in patients with pathological stage I non-small cell lung cancer following resection. 
  • Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma. 
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. 
  • Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases. 
  • Function in elderly cancer survivors depends on comorbidities. 
  • Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. 
  • Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI. 
  • Functional assessment and the cancer survivor: something old, something new. 
  • Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. 
  • GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. 
  • GPR54 is a target for suppression of metastasis in endometrial cancer. 
  • Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. 
  • Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. 
  • Gastric adenocarcinoma: CT versus surgical staging. 
  • Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. 
  • Gastric cancer. Clinical practice guidelines in oncology. 
  • Gastrointestinal carcinoids: characterization by site of origin and hormone production. 
  • Gastrointestinal imaging: endoscopic ultrasound. 
  • Gene expression patterns that characterize advanced stage serous ovarian cancers. 
  • Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. 
  • Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. 
  • Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. 
  • Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. 
  • Gene expression profiling in melanoma: past results and future potential. 
  • Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. 
  • Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. 
  • Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. 
  • Genetic profiling to predict recurrence of early cervical cancer. 
  • Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. 
  • Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. 
  • Genetic variants in nucleotide excision repair pathway predict survival of esophageal squamous cell cancer patients receiving platinum-based chemotherapy. 
  • Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. 
  • Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. 
  • Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. 
  • Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. 
  • Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. 
  • Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. 
  • Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. 
  • Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. 
  • Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. 
  • Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. 
  • Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. 
  • Guideline Adherence and Practice Patterns in the Management of Medullary Thyroid Cancer. 
  • HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. 
  • Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. 
  • Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. 
  • Head and neck cancers. 
  • Head and neck cancers. 
  • Head and neck cancers. 
  • Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. 
  • Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. 
  • Health impact of head and neck cancer. 
  • Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. 
  • Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. 
  • Hepatocellular adenoma among adult survivors of childhood and young adult cancer. 
  • Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. 
  • Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. 
  • High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. 
  • High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. 
  • High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. 
  • High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. 
  • High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. 
  • High-resolution MR imaging of the breast: clinical context. 
  • High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. 
  • High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). 
  • Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. 
  • Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. 
  • Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. 
  • Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. 
  • Hodgkin disease: clinical utility of CT in initial staging and treatment. 
  • Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. 
  • Hodgkin lymphoma, version 2.2015. 
  • Hodgkin lymphoma. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Hope and social support utilisation among different age groups of women with breast cancer and their spouses. 
  • How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer. 
  • How Long Should Patients with Cystic Lesions of the Pancreas Be Followed? 
  • How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. 
  • How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. 
  • How oncologists and their patients with advanced cancer communicate about health-related quality of life. 
  • How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. 
  • Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. 
  • Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. 
  • Human papillomavirus in early laryngeal carcinoma. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. 
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 
  • I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. 
  • Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. 
  • Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. 
  • Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. 
  • Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. 
  • If histology matters.. 
  • Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. 
  • Imaging in Patients with Cirrhosis: Current Evidence. 
  • Imaging lung cancer. 
  • Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. 
  • Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. 
  • Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. 
  • Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. 
  • Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. 
  • Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. 
  • Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. 
  • Immunoreaction at 43 kDa with anti-ubiquitin antibody in breast neoplasms. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. 
  • Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer. 
  • Impact of Cavity Shave Margins on Margin Status in Patients with Pure Ductal Carcinoma In Situ. 
  • Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus. 
  • Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. 
  • Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. 
  • Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. 
  • Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. 
  • Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. 
  • Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. 
  • Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. 
  • Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. 
  • Impact of T status and N status on perioperative outcomes after thoracoscopic lobectomy for lung cancer. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of Time to Endoscopic Resection on Outcomes for Stage I Esophageal Adenocarcinoma. 
  • Impact of Timeliness of Resection and Thyroidectomy Margin Status on Survival for Patients with Anaplastic Thyroid Cancer: An Analysis of 335 Cases. 
  • Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma. 
  • Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. 
  • Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. 
  • Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. 
  • Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. 
  • Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. 
  • Impact of laparoscopic staging in the treatment of pancreatic cancer. 
  • Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. 
  • Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. 
  • Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. 
  • Impact of pre-operative positron emission tomography in gallbladder cancer. 
  • Impact of preepiglottic space tumor involvement on concurrent chemoradiation therapy. 
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. 
  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. 
  • Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. 
  • Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC-0, A and B hepatocellular carcinoma. 
  • Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. 
  • Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. 
  • Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. 
  • Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia. 
  • Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. 
  • Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. 
  • Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. 
  • Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. 
  • Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. 
  • Incidence and risk factors of significant carotid artery stenosis in asymptomatic survivors of head and neck cancer after radiotherapy. 
  • Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). 
  • Incidence of autoimmune disease in patients after breast reconstruction with silicone gel implants versus autogenous tissue: a preliminary report. 
  • Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. 
  • Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? 
  • Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? 
  • Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. 
  • Increased erbB-2 gene copies and expression in multiple stages of breast cancer. 
  • Increased microvascular density predicts relapse in Wilms' tumor. 
  • Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. 
  • Increased skin carcinogenesis in caspase-activated DNase knockout mice. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. 
  • Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. 
  • Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. 
  • Indications for adjuvant radiotherapy in extrapelvic colonic carcinoma. 
  • Indocyanine Green Fluorescence Imaging with Lymphoscintigraphy for Sentinel Node Biopsy in Melanoma: Increasing the Sentinel Lymph Node-Positive Rate. 
  • Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer. 
  • Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. 
  • Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. 
  • Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. 
  • Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer. 
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. 
  • Initiation of salvage therapy for prostate cancer. 
  • Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • Insurance status, stage of presentation, and survival among female patients with head and neck cancer. 
  • Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution. 
  • Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. 
  • Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. 
  • Intercellular junctions and tumor stage in small cell carcinoma of the lung. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. 
  • International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. 
  • International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. 
  • International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 
  • Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. 
  • Interval to treatment in endometrial cancer. 
  • Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. 
  • Intraductal Oncocytic Papillary Neoplasms: Clinical-Pathologic Characterization of 24 Cases, With An Emphasis on Associated Invasive Carcinomas. 
  • Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. 
  • Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? 
  • Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative radiation therapy in resected bile duct cancer. 
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. 
  • Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. 
  • Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Introduction: current controversies in rectal cancer. 
  • Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. 
  • Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. 
  • Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. 
  • Invasive Mediastinal Staging for Lung Cancer by The Society of Thoracic Surgeons Database Participants. 
  • Invasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Investigating 3D tumor distribution for optimized diagnosis of prostate cancer. 
  • Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer. 
  • Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia. 
  • Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer. 
  • Investment in new technology research can save future health care dollars. 
  • Invited commentary. 
  • Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures. 
  • Is Excisional Biopsy Needed for Pure FEA Diagnosed on a Core Biopsy? 
  • Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate? 
  • Is intraoperative lymph node mapping and sentinel lymph node biopsy for colorectal carcinoma necessary? 
  • Is port site resection necessary in the surgical management of gallbladder cancer? 
  • Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion? 
  • Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance? 
  • Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis? 
  • Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. 
  • Is there a role for sentinel lymph node biopsy in the management of sarcoma? 
  • Is tumor response important for renal carcinoma? 
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. 
  • JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. 
  • Juvenile malignant melanoma. 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Kidney cancer. 
  • Kidney cancer. Clinical practice guidelines in oncology. 
  • Kidney cancer. Clinical practice guidelines. 
  • Knowledge of indications and utilization of EUS: a survey of oncologists in the United States. 
  • LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. 
  • LI-RADS: a glimpse into the future. 
  • Label-Free Imaging of Female Genital Tract Melanocytic Lesions With Pump-Probe Microscopy: A Promising Diagnostic Tool. 
  • Lack of correlation between short- and long-term performance after lung cancer surgery. 
  • Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. 
  • Laparoscopic colon resection for cancer. 
  • Laparoscopic hand assisted radical cystectomy with ileal conduit urinary diversion. 
  • Laparoscopic staging for hepatobiliary carcinoma. 
  • Laparoscopy and peripancreatic neoplasia. 
  • Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 
  • Large anterior mediastinal mass in an infant. 
  • Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells. 
  • Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. 
  • Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype. 
  • Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. 
  • Liver angiomyolipomas: a clinical, radiologic, and pathologic analysis of 22 patients from a single center. 
  • Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. 
  • Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. 
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. 
  • Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Local excision results in comparable survival to radical resection for early-stage rectal carcinoid. 
  • Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. 
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy. 
  • Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. 
  • Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. 
  • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). 
  • Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 
  • Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. 
  • Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Location of the Tumor is a "Central" Predictor of Nodal (N1) Upstaging. 
  • Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. 
  • Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. 
  • Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. 
  • Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. 
  • Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis. 
  • Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. 
  • Long-term results of therapy for stage C neuroblastoma. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. 
  • Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. 
  • Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. 
  • Longitudinal Follow-up of Lung Cancer Resection From the Society of Thoracic Surgeons General Thoracic Surgery Database in Patients 65 Years and Older. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Loss of KAI1 expression in the progression of colorectal cancer. 
  • Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. 
  • Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. 
  • Low contralateral neck recurrence risk with ipsilateral neck radiotherapy in N2b tonsillar squamous cell carcinoma. 
  • Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer. 
  • Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. 
  • Low-Volume Lymph Node Metastases in Endometrial Carcinoma. 
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. 
  • Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. 
  • Lung cancer and positron emission tomography with fluorodeoxyglucose. 
  • Lung cancer heterogeneity. Prognostic implications. 
  • Lung cancer in the elderly. 
  • Lung cancer in the elderly. 
  • Lung cancer management in 2010. 
  • Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. 
  • Lung cancer staging: proteomics. 
  • Lung-cancer screening. 
  • Lymph node staging in potentially curable prostatic carcinoma. 
  • Lymph node staging of potentially curable prostatic carcinoma. 
  • Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. 
  • Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. 
  • Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. 
  • Lymphatic mapping and sentinel node identification for colorectal cancer. 
  • Lymphoma of the female genital tract: current status. 
  • Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases. 
  • Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. 
  • MDCT urography of upper tract urothelial neoplasms. 
  • MDM4 genetic variants and risk of gastric cancer in an Eastern Chinese population. 
  • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. 
  • MOLECULAR PROGNOSTICS FOR UVEAL MELANOMA. 
  • MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. 
  • MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. 
  • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 
  • Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. 
  • Magnetic resonance spectroscopic studies of the prostate. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Malignant Melanoma: Diagnostic and Management Update. 
  • Malignant melanoma in black Americans. A trend toward improved survival. 
  • Malignant melanoma in the elderly. 
  • Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. 
  • Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. 
  • Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations. 
  • Management of Locoregional Rectal Cancer. 
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 
  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. 
  • Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Management of solid tumors in children. 
  • Management strategies for patients with advanced rectal cancer and liver metastases using modified Delphi methodology: results from the PelvEx Collaborative. 
  • Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience. 
  • Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. 
  • Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. 
  • Matched-pair analysis of race or ethnicity in outcomes of head and neck cancer patients receiving similar multidisciplinary care. 
  • Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma. 
  • Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. 
  • Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. 
  • Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung Cancer. 
  • Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. 
  • Medical malpractice and prostate brachytherapy. 
  • Melanoma of the ear: treatment and survival probabilities based on 199 patients. 
  • Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. 
  • Melanoma quality of life: pilot study using utility measurements. 
  • Melanoma-associated retinopathy: a presenting sign of metastatic disease. 
  • Melastatin expression and prognosis in cutaneous malignant melanoma. 
  • Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. 
  • Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors. 
  • Metastatic breast cancer: Who benefits from surgery? 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. 
  • Microarray analysis of gene expression in gynecologic cancers--still only the beginning. 
  • Microbial dysbiosis is associated with human breast cancer. 
  • Microsatellite Instability Is Common in Colorectal Cancer in Native Nigerians. 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. 
  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. 
  • Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy. 
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 
  • Minimally Invasive Versus Open Esophagectomy for Esophageal Cancer: A Population-Based Analysis. 
  • Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. 
  • Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. 
  • Molecular and clonal evolution in recurrent metastatic gliosarcoma. 
  • Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. 
  • Molecular approaches to prevention and detection of epithelial ovarian cancer. 
  • Molecular biologic staging of esophageal cancer. 
  • Molecular biologic staging of lung cancer. 
  • Molecular biologic substaging of non-small cell lung cancer. 
  • Molecular biologic substaging of stage I NSCLC through immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue. 
  • Molecular biologic substaging of stage I lung cancer according to gender and histology. 
  • Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. 
  • Molecular markers in prostate cancer: the role in preoperative staging. 
  • Molecular markers of therapeutic resistance in breast cancer. 
  • Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. 
  • Molecular staging and the selection of therapy for non-small cell lung cancer. 
  • Molecular staging of lung and esophageal cancer. 
  • Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. 
  • Molecular staging of malignant melanoma: correlation with clinical outcome. 
  • Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. 
  • Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. 
  • Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. 
  • Morphometric quantitation of tumor necrosis in stage 1 non-small cell carcinoma of lung: prognostic implications. 
  • Morphomics predicts response to ipilimumab in patients with stage IV melanoma. 
  • Mucosal melanoma of the head and neck. 
  • Mucosal melanoma. 
  • Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). 
  • Multi-institutional Care in Clinical Stage II and III Esophageal Cancer. 
  • Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. 
  • Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. 
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. 
  • Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? 
  • Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. 
  • Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. 
  • Multidisciplinary care of patients with early-stage breast cancer. 
  • Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches. 
  • Multimodal therapy of prostatic cancer. 
  • Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. 
  • Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. 
  • Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. 
  • Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. 
  • Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. 
  • Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. 
  • Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer. 
  • Multiple myeloma in the elderly. 
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. 
  • Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. 
  • Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen. 
  • Multivariate procedures to describe clinical staging of melanoma. 
  • Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. 
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • NCCN Clinical Practice Guidelines in Oncology: colon cancer. 
  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. 
  • NCCN Clinical Practice Guidelines in Oncology: rectal cancer. 
  • NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. 
  • NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • NCCN Guidelines Insights: Breast Cancer, Version 1.2017. 
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. 
  • NCCN Guidelines Insights: Melanoma, Version 3.2016. 
  • NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. 
  • NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. 
  • NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening. 
  • NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. 
  • NCCN clinical practice guidelines in oncology. Anal carcinoma. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Nasal Cavity Squamous Cell Carcinoma: Factors Associated With Treatment Outcomes and Potential Organ Preservation. 
  • National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. 
  • National Trends in Management of Pathologic Stage III Melanoma. 
  • National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002. 
  • Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. 
  • Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. 
  • Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. 
  • Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States. 
  • Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer. 
  • New Developments in the Management of Cutaneous Squamous Cell Carcinoma. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • New advances in focal therapy for early stage prostate cancer. 
  • Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. 
  • Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. 
  • Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 
  • Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 
  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. 
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 
  • No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. 
  • Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Node biopsy vs. full lymph node dissection for breast cancer. 
  • Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. 
  • Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. 
  • Non-Hodgkin's lymphoma. Biologic classification and implication for therapy. 
  • Non-Hodgkin's lymphomas, version 4.2014. 
  • Non-Hodgkin's lymphomas. 
  • Non-Hodgkin's lymphomas. 
  • Non-randomized comparative study of irradiation alone or in combination with surgery in stage Ib, IIa and "proximal" IIb carcinoma of the cervix. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Non-small cell lung cancer: FDG-PET imaging. 
  • Noninvasive clinical staging modalities for lung cancer. 
  • Noninvasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study. 
  • Nonsurgical approach in stage I and stage II breast cancer. 
  • Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. 
  • Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. 
  • Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. 
  • Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension. 
  • Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. 
  • Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). 
  • Nutritional parameters affecting erythrocyte polyamine levels in cancer patients. 
  • OVX1 as a marker for early stage endometrial carcinoma. 
  • Obesity and mortality after locoregional breast cancer diagnosis. 
  • Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. 
  • Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. 
  • Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. 
  • Ocular neoplastic disease. 
  • Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. 
  • Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data. 
  • Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size < 2 cm: a systematic review and meta-analysis. 
  • Open surgical partial nephrectomy for upper tract urothelial carcinoma. 
  • Open versus laparoscopic portal lymphadenectomy in gallbladder cancer: is there a difference in lymph node yield? 
  • Operative techniques in early-stage lung cancer. 
  • Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. 
  • Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? 
  • Optimal staging procedures, including imaging, to define prognosis of bladder cancer. 
  • Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. 
  • Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. 
  • Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute. 
  • Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. 
  • Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. 
  • Oropharyngeal carcinoma treated with radiotherapy: a 30-year experience. 
  • Osteogenic sarcoma of the head and neck. The UCLA experience. 
  • Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. 
  • Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. 
  • Outcomes after surgical management of synchronous bilateral primary lung cancers. 
  • Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma. 
  • Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. 
  • Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. 
  • Outcomes in surgical stage I uterine papillary serous carcinoma. 
  • Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. 
  • Outcomes of Single Node Excision Compared with Lymph Node Dissection for Patients with Clinical Stage III N1b Cutaneous Melanoma. 
  • Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. 
  • Outcomes of patients with a pretransplant history of early-stage melanoma. 
  • Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016. 
  • Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer. 
  • Outcomes of surgical revascularization for lower extremity arterial thromboembolism in patients with advanced malignancy. 
  • Ovarian cancer. Clinical practice guidelines in oncology. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • Overexpressed BAG3 is a potential therapeutic target in chronic lymphocytic leukemia. 
  • Overexpression and mutation of p53 in endometrial carcinoma. 
  • Overexpression and mutation of p53 in epithelial ovarian cancer. 
  • Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 
  • Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. 
  • Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. 
  • Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • PET Imaging for Head and Neck Cancers. 
  • PET Imaging of Oral Cavity and Oropharyngeal Cancers. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 
  • PET/Computed Tomography: Laryngeal and Hypopharyngeal Cancers. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. 
  • Pain in the head and neck cancer patient: changes over treatment. 
  • Pain, quality of life, and spinal accessory nerve status after neck dissection. 
  • Palliative Care Awareness Among Advanced Cancer Patients and Their Family Caregivers in Singapore. 
  • Palliative thoracic radiotherapy in advanced lung cancer: A single institution experience. 
  • Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. 
  • Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. 
  • Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: the actual 5-year survivors. 
  • Panel of serum biomarkers for the diagnosis of lung cancer. 
  • Paraganglioma of the head and neck: long-term local control with radiotherapy. 
  • Partitioning of time trends in prevalence and mortality of lung cancer. 
  • Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter? 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. 
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. 
  • Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. 
  • Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. 
  • Pathological downstaging does not guide the need for IORT in primary locally advanced rectal cancer. 
  • Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. 
  • Patient Preferences in Treatment Choices for Early-Stage Lung Cancer. 
  • Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. 
  • Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. 
  • Patient preferences in advanced or recurrent ovarian cancer. 
  • Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. 
  • Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer. 
  • Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer. 
  • Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma. 
  • Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. 
  • Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. 
  • Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer. 
  • Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. 
  • Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. 
  • Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. 
  • Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysis. 
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 
  • Patterns of tumor spread and risk of fracture and epidural impingement in metastatic vertebrae. 
  • Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer. 
  • Pediatric melanoma. 
  • Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. 
  • Pelvic lymphadenectomy is not essential to staging accuracy in all patients with localized prostate cancer. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study. 
  • Percent tumor involvement and risk of biochemical progression after radical prostatectomy. 
  • Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. 
  • Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. 
  • Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. 
  • Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Associated PDAC : A Multi-institutional Analysis. 
  • Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Perioperative Management of Adrenalectomy and Inferior Vena Cava Reconstruction in a Patient With a Large, Malignant Pheochromocytoma With Vena Caval Extension. 
  • Perioperative Outcomes and 5-year Survival After Open versus Thoracoscopic Sleeve Resection for Lung Cancer. 
  • Perioperative Outcomes and Survival After Preoperative Immunotherapy for Non-Small Cell Lung Cancer. 
  • Perioperative blood transfusion in patients with colon carcinoma. 
  • Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer. 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Peritoneal cytology and invasive carcinoma of the cervix. 
  • Peritumoral expression of adipokines and fatty acids in breast cancer. 
  • Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. 
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. 
  • Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. 
  • Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. 
  • Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). 
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. 
  • Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. 
  • Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. 
  • Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 
  • Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. 
  • Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. 
  • Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. 
  • Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. 
  • Phase II study of carboplatin in children with progressive low-grade gliomas. 
  • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. 
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 
  • Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. 
  • Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. 
  • Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of intravenous melphalan in advanced colorectal carcinoma. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. 
  • Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). 
  • Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). 
  • Physical activity in patients with advanced-stage cancer: a systematic review of the literature. 
  • Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). 
  • Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. 
  • Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). 
  • Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. 
  • Placental site trophoblastic tumor presenting as a friable cervical mass. 
  • Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. 
  • Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. 
  • Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. 
  • Ploidy analysis of epithelial ovarian cancers using image cytometry. 
  • Pneumoperitoneum complicating ERCP performed immediately after EUS-guided fine needle aspiration. 
  • Point: Should UItrasonographic Endoscopy Be the Preferred Modality for Staging of Lung Cancer? Yes. 
  • Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. 
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. 
  • Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. 
  • Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer. 
  • Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. 
  • Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck. 
  • Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. 
  • Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. 
  • Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. 
  • Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. 
  • Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. 
  • Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. 
  • Positron emission tomography imaging in the thorax. 
  • Positron emission tomography in radiation treatment planning: the potential of metabolic imaging. 
  • Positron emission tomography scanning in malignant melanoma. 
  • Post-mastectomy radiation in large node-negative breast tumors: does size really matter? 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study. 
  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 
  • Postoperative Pain Scores and Narcotic Use in Robotic-assisted Versus Laparoscopic Hysterectomy for Endometrial Cancer Staging. 
  • Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer. 
  • Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. 
  • Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. 
  • Postoperative radiation therapy for lung cancer: where do we stand? 
  • Postoperative radiotherapy is associated with improved overall survival for alveolar ridge squamous cell carcinoma with adverse pathologic features. 
  • Postradical prostatectomy irradiation in carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. 
  • Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. 
  • Posttraumatic growth and health-related quality of life in a racially diverse cohort of breast cancer survivors. 
  • Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. 
  • Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. 
  • Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. 
  • Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. 
  • Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. 
  • Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals. 
  • Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. 
  • Predicting a local recurrence after breast-conserving therapy by gene expression profiling. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. 
  • Predicting non-organ-confined prostate cancer in men diagnosed after 2000. 
  • Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC/UICC staging system. 
  • Predicting recurrence patterns after resection of hepatocellular cancer. 
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score. 
  • Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. 
  • Prediction model to estimate overall survival benefit of postoperative radiotherapy for resected major salivary gland cancers. 
  • Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. 
  • Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. 
  • Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. 
  • Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. 
  • Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. 
  • Predictive value of initial imaging and staging with long-term outcomes in young adults diagnosed with colorectal cancer. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival. 
  • Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). 
  • Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. 
  • Predictors of extracapsular extension and positive margins in African American and white men. 
  • Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. 
  • Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. 
  • Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. 
  • Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Predictors of stage at presentation and outcomes of head and neck cancers in a university hospital setting. 
  • Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. 
  • Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. 
  • Preference weights for chemotherapy side effects from the perspective of women with breast cancer. 
  • Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. 
  • Preoperative Evaluation and Indications for Pulmonary Metastasectomy. 
  • Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. 
  • Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. 
  • Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. 
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. 
  • Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. 
  • Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. 
  • Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap? 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. 
  • Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. 
  • Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. 
  • Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 
  • Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. 
  • Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. 
  • Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. 
  • Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. 
  • Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. 
  • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 
  • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. 
  • Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma. 
  • Prevalence, characteristics, and outcomes of HIV-positive women diagnosed with invasive cancer of the cervix in Kenya. 
  • Prevertebral muscle involvement in nasopharyngeal carcinoma. 
  • Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. 
  • Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Primary chemotherapy in epithelial ovarian cancer. 
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. 
  • Primary gastrointestinal lymphoma. 
  • Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. 
  • Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. 
  • Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. 
  • Primary radiation therapy for early glottic cancer. 
  • Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. 
  • Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. 
  • Primary systemic therapy in breast cancer: past lessons and new approaches. 
  • Primary treatment of advanced ovarian cancer: how does the 'real world' practice? 
  • Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. 
  • Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. 
  • Prognostic Communication Between Oncologists and Parents of Children With Advanced Cancer. 
  • Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. 
  • Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic Value of the Staging System for Eyelid Tumors in the 7th Edition of the American Joint Committee on Cancer Staging Manual. 
  • Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). 
  • Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. 
  • Prognostic factors impacting survival in early stage uterine carcinosarcoma. 
  • Prognostic factors in head and neck melanoma. Effect of lesion location. 
  • Prognostic factors in low-stage nonseminomatous testicular cancer. 
  • Prognostic factors in renal adenocarcinoma. 
  • Prognostic factors in renal cancer. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? 
  • Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. 
  • Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. 
  • Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. 
  • Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer. 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. 
  • Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience. 
  • Prognostic indicators for survival in stage I carcinoma of the lung: a histologic study of 47 surgically resected cases. 
  • Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. 
  • Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. 
  • Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease. 
  • Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. 
  • Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. 
  • Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. 
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. 
  • Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. 
  • Prognostic significance of surgical margins after transoral laser microsurgery for early-stage glottic squamous cell carcinoma. 
  • Prognostic significance of the highest peripancreatic lymph node in biliary tract adenocarcinoma. 
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. 
  • Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 
  • Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. 
  • Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. 
  • Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. 
  • Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 
  • Progress in breast cancer-can we do better? 
  • Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. 
  • Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. 
  • Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. 
  • Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. 
  • Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? 
  • Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. 
  • Proper staging techniques in testicular cancer patients. 
  • Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer. 
  • Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. 
  • Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. 
  • Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. 
  • Prospective studies of neck dissection specimens support preservation of sublevel IIB for laryngeal squamous carcinoma with clinically negative neck. 
  • Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Prostate Cancer, Version 1.2016. 
  • Prostate biopsy in selecting candidates for hemiablative focal therapy. 
  • Prostate biopsy quantitative histology as a staging and prognostic factor. 
  • Prostate brachytherapy: a descriptive analysis from CaPSURE. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer early detection practices among men with a family history of disease. 
  • Prostate cancer in young men: an important clinical entity. 
  • Prostate cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. 
  • Prostate cancer, version 1.2014. 
  • Prostate cancer. 
  • Prostate cancer: an evolving paradigm. 
  • Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. 
  • Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. 
  • Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. 
  • Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. 
  • Prostate specific antigen: a decade of discovery--what we have learned and where we are going. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. 
  • Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. 
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. 
  • Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. 
  • Prostatic malignancy. 
  • Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. 
  • Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. 
  • Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma. 
  • Quality of life after breast cancer diagnosis and survival. 
  • Quality of life after isolated limb infusion for in-transit melanoma of the extremity. 
  • Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. 
  • Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). 
  • Quantifying the safety benefits of wedge resection: a society of thoracic surgery database propensity-matched analysis. 
  • Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. 
  • Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. 
  • Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. 
  • RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. 
  • RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. 
  • RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. 
  • Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities. 
  • Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). 
  • Race, anthropometric factors, and stage at diagnosis of breast cancer. 
  • Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. 
  • Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations. 
  • Racial and Ethnic Differences in Lung Cancer Surgical Stage: An STS Database Study. 
  • Racial and ethnic disparities in palliative care utilization among gynecological cancer patients. 
  • Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases. 
  • Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation. 
  • Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care. 
  • Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. 
  • Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 
  • Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. 
  • Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer. 
  • Radiation Records in the National Cancer Database: Variations in Coding and/or Practice Can Significantly Alter Survival Results. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. 
  • Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone. 
  • Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma^. 
  • Radiation therapy in stage II and III rectal cancer. 
  • Radiation therapy in the management of rectal cancer. 
  • Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer. 
  • Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. 
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. 
  • Radical hysterectomy in obese women. 
  • Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. 
  • Radical radiotherapy for T4 carcinoma of the skin of the head and neck: a multivariate analysis. 
  • Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. 
  • Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. 
  • Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. 
  • Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity. 
  • Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. 
  • Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy. 
  • Radiotherapy regimens in patients with nonmelanoma head and neck skin cancers. 
  • Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. 
  • Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. 
  • Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. 
  • Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. 
  • Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). 
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 
  • Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. 
  • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 
  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. 
  • Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. 
  • Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. 
  • Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. 
  • Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. 
  • Rb and p16INK4a expression in resected non-small cell lung tumors. 
  • Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. 
  • Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Readmission after pancreatic resection: causes and causality pattern. 
  • Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. 
  • Reassessing hepatocellular carcinoma staging in a changing patient population. 
  • Rebuttal from drs Wahidi and Ernst. 
  • Recent advances in de novo CD5+ diffuse large B cell lymphoma. 
  • Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix. 
  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 
  • Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Rectal cancer. 
  • Rectal cancer: presentation with metastatic and locally advanced disease. American College of Radiology. ACR Appropriateness Criteria. 
  • Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. 
  • Rectourethral fistula after combination radiotherapy for prostate cancer. 
  • Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. 
  • Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. 
  • Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. 
  • Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. 
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. 
  • Recurrent malignant melanoma: the identification of prognostic factors to predict survival. 
  • Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. 
  • Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? 
  • Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. 
  • Regional spread of cutaneous squamous cell carcinoma of the face via facial vein tumor thrombus: a case report. 
  • Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. 
  • Relation between p53 overexpression and established prognostic factors in breast cancer. 
  • Relationship between disease-free interval and survival in patients with recurrent melanoma. 
  • Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. 
  • Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. 
  • Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. 
  • Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. 
  • Renal mass anatomic characteristics and perioperative outcomes of laparoscopic partial nephrectomy: a critical analysis. 
  • Renal medullary carcinoma: A national analysis of 159 patients. 
  • Reproducibility of CT Radiomic Features within the Same Patient: Influence of Radiation Dose and CT Reconstruction Settings. 
  • Resected irradiated rectal cancers: Are twelve lymph nodes really necessary in the era of neoadjuvant therapy? 
  • Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial. 
  • Resection of adrenocortical carcinoma liver metastasis: is it justified? 
  • Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. 
  • Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. 
  • Resection of the irradiated esophagus: the impact of lymph node yield on survival. 
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. 
  • Resistance exercise training in patients with genitourinary cancers to mitigate treatment-related skeletal muscle loss. 
  • Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. 
  • Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of radiation therapy in gastric cancer. 
  • Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. 
  • Results of treatment of stage 3A Hodgkin's disease. 
  • Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer. 
  • Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. 
  • Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. 
  • Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. 
  • Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. 
  • Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. 
  • Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. 
  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Rising incidence of late-stage head and neck cancer in the United States. 
  • Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Risk factors for perineal seeding of prostate cancer after needle biopsy. 
  • Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. 
  • Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. 
  • Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes. 
  • Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck. 
  • Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. 
  • Role of Adjuvant Radiotherapy in Locally Advanced Colonic Carcinoma in the Modern Chemotherapy Era. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. 
  • Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. 
  • Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. 
  • Role of induction chemotherapy in sinonasal malignancies: a systematic review. 
  • Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. 
  • Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. 
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. 
  • Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. 
  • Rotationplasty after failed limb-sparing tumor surgery: a report of two cases. 
  • Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Rt-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. 
  • Rural health disparities in melanoma staging and prognostic outcomes in Iowa. 
  • S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. 
  • SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study. 
  • SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. 
  • SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 
  • Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies. 
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. 
  • Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. 
  • Sarcopenia as a prognostic factor among patients with stage III melanoma. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Screening for cancers of the head and neck: addressing the problem. 
  • Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. 
  • Screening for lung cancer. 
  • Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). 
  • Segmentectomy and Lung Cancer: Why, When, How, and How Good? 
  • Selection of patients for heterotopic implantation of the areola and nipple. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies. 
  • Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. 
  • Sentinel Lymph Node Technique in Endometrial Cancer. 
  • Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? 
  • Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 
  • Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. 
  • Sentinel node biopsy for head and neck melanoma: a systematic review. 
  • Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. 
  • Sentinel node staging of resectable colon cancer: results of a multicenter study. 
  • Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. 
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. 
  • Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. 
  • Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. 
  • Serum cotinine concentration and wound complications in head and neck reconstruction. 
  • Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Sex related survival differences in instances of melanoma. 
  • Should all branch-duct intraductal papillary mucinous neoplasms be resected? 
  • Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. 
  • Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. 
  • Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. 
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. 
  • Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. 
  • Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. 
  • Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist. 
  • Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"? 
  • Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. 
  • Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival. 
  • Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). 
  • Small bowel obstruction after transoral robotic surgery. 
  • Small cell lung cancer. 
  • Small cell lung cancer. 
  • Small neuroendocrine lesions in intrathoracic lymph nodes of patients with primary lung adenocarcinoma: real metastasis? 
  • Small-cell lung cancer: a review of clinical trials. 
  • Small-cell lung cancer: prognostic factors and changing treatment over 15 years. 
  • Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. 
  • Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. 
  • Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. 
  • Specific keynote: genome copy number abnormalities in ovarian cancer. 
  • Sphincter preservation in rectal cancer. 
  • Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. 
  • Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. 
  • Spontaneous hemorrhage associated with a pilomyxoid astrocytoma. Case report. 
  • Squamous carcinoma of urinary bladder. 
  • Squamous cell carcinoma arising in inverted papilloma. 
  • Squamous cell carcinoma of the buccal mucosa. 
  • Squamous cell carcinoma of the oropharynx and hypopharynx. 
  • Squamous cell carcinoma of the temporal bone: a radiographic-pathologic correlation. 
  • Stage 1 small cell cancer of the vagina. 
  • Stage I NSCLC: elucidating the prognostic factors. 
  • Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. 
  • Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. 
  • Stage IA non-small cell lung cancer: a small proportion of cases in the general population. 
  • Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment. 
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. 
  • Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. 
  • Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. 
  • Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. 
  • Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? 
  • Staging evaluation for patients with adenocarcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Staging of colorectal cancer: past, present, and future. 
  • Staging of esophageal cancer by EUS: staging accuracy revisited. 
  • Staging of pancreatic cancer before and after neoadjuvant chemoradiation. 
  • Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. 
  • Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. 
  • Staging techniques for lung cancer. 
  • State Medicaid expansion status, insurance coverage and stage at diagnosis in head and neck cancer patients. 
  • Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. 
  • Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer. 
  • Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. 
  • Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. 
  • Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. 
  • Sternal metastasis as first presentation of a well-differentiated papillary thyroid carcinoma. 
  • Steroid premedication before i.v. contrast-enhanced CT resulting in resolution of lymphadenopathy. 
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. 
  • Stratification of risk factors in renal cell carcinoma. 
  • Stress buffering effects of daily spousal support on women's daily emotional and physical experiences in the context of breast cancer concerns. 
  • Study Design and Rationale: A Multicenter, Prospective Trial of Electromagnetic Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules (ALL IN ONE Trial). 
  • Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. 
  • Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs. 
  • Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). 
  • Sunitinib efficacy against advanced renal cell carcinoma. 
  • Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. 
  • Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. 
  • Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. 
  • Surgery for Men with Breast Cancer: Do the Same Data Still Apply? 
  • Surgery for palliation and treatment of advanced breast cancer. 
  • Surgery of the primary tumor does not improve survival in stage IV breast cancer. 
  • Surgery versus stereotactic body radiation therapy for operable stage I non-small cell lung cancer: Can we achieve equipoise? 
  • Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. 
  • Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-Stage Lung Cancer. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. 
  • Surgical Resection is Justifiable for Oral T4b Squamous Cell Cancers With Masticator Space Invasion. 
  • Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone. 
  • Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis. 
  • Surgical candidacy and treatment initiation among women with cervical cancer at public referral hospitals in Kampala, Uganda: a descriptive cohort study. 
  • Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. 
  • Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. 
  • Surgical management and prognosis of renal cell carcinoma invading the vena cava. 
  • Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical management of high-risk, localized prostate cancer. 
  • Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. 
  • Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. 
  • Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival? 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). 
  • Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? 
  • Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. 
  • Surgically Managed Clinical Stage IIIA-Clinical N2 Lung Cancer in The Society of Thoracic Surgeons Database. 
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. 
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. 
  • Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. 
  • Survival after radiation for stage I and II non-small cell lung cancer with positive margins. 
  • Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. 
  • Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. 
  • Survival in the elderly after pneumonectomy for early-stage non-small cell lung cancer: a comparison with nonoperative management. 
  • Survival outcomes in sinonasal carcinoma with neuroendocrine differentiation: A NCDB analysis. 
  • Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. 
  • Synchronous resection of primary and liver metastases for neuroendocrine tumors. 
  • Synovial sarcoma of the foot and ankle. 
  • Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. 
  • Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? 
  • Systemic therapy for older women with breast cancer. 
  • Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. 
  • T classification and clivus margin as risk factors for determining locoregional control by radiotherapy of nasopharyngeal carcinoma. 
  • T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. 
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. 
  • TGFβ1 Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy. 
  • TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). 
  • Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. 
  • Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy. 
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. 
  • Temporal trends in the management of potentially resectable lung cancer. 
  • Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. 
  • Testicular cancer. Clinical practice guidelines. 
  • Testicular carcinoma. 
  • The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. 
  • The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer. 
  • The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. 
  • The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). 
  • The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? 
  • The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. 
  • The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). 
  • The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy. 
  • The Effect of Tumor Size and Histologic Findings on Outcomes After Segmentectomy vs Lobectomy for Clinically Node-Negative Non-Small Cell Lung Cancer. 
  • The Effects of Surgery Type and Chemotherapy on Early-Stage Breast Cancer Patients' Quality of Life Over 2-Year Follow-up. 
  • The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. 
  • The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. 
  • The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. 
  • The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. 
  • The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules. 
  • The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma: A Pooled Data Analysis. 
  • The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. 
  • The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes. 
  • The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. 
  • The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth. 
  • The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. 
  • The Quality of Peer-Reviewed Publications on Surgery for Early Stage Lung Cancer Within the Veterans Health Administration. 
  • The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. 
  • The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. 
  • The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. 
  • The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis. 
  • The Role of Surgery for Pancreatic Neuroendocrine Tumors. 
  • The Selective Use of Radiation Therapy in Rectal Cancer Patients. 
  • The Society of Thoracic Surgeons Composite Score Rating for Pulmonary Resection for Lung Cancer. 
  • The Texas Breast Screening Project: Part I. Mammographic and clinical results. 
  • The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer. 
  • The ability of tumor volume to predict local control in surgically treated squamous cell carcinoma of the supraglottic larynx. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. 
  • The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. 
  • The adrenal mass: correlation of histopathology with imaging. 
  • The anatomy of missed breast cancers. 
  • The association between progesterone receptor expression and survival in women with adult granulosa cell tumors. 
  • The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. 
  • The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes. 
  • The challenge of systematic reviews of diagnostic and staging studies in cancer. 
  • The chemoradiation paradigm in head and neck cancer. 
  • The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer. 
  • The effect of Guidelines in surgical decision making: The paradigm of hepatocellular carcinoma. 
  • The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer. 
  • The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. 
  • The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The effect of radiation therapy on microcystic adnexal carcinoma: a case report. 
  • The effect of the setting of a positive surgical margin in soft tissue sarcoma. 
  • The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. 
  • The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. 
  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma. 
  • The efficacy of full-lung tomography in the detection of early metastatic disease from melanoma. 
  • The expression of Claudin-4 in gastric cancer tissue: A single center experience. 
  • The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? 
  • The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. 
  • The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. 
  • The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of age on thyroid cancer staging. 
  • The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts. 
  • The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. 
  • The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. 
  • The impact of shave biopsy on the management of patients with thin melanomas. 
  • The impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent Rectal Cancer. 
  • The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer. 
  • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. 
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. 
  • The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. 
  • The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. 
  • The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. 
  • The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. 
  • The natural course of prostatic carcinoma in relation to initial cytological grade. 
  • The natural history of mammographic calcifications subjected to interval follow-up. 
  • The need for standardized pathologic staging of pancreaticoduodenectomy specimens. 
  • The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. 
  • The number of lymph nodes dissected in breast cancer patients influences the accuracy of prognosis. 
  • The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients. 
  • The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. 
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. 
  • The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. 
  • The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. 
  • The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. 
  • The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? 
  • The relationship of collagenolytic activity to stage of human colorectal carcinoma. 
  • The relevance of stage A malignancy in prostatic cancer. 
  • The rise of ablative technologies for treating the small renal mass. 
  • The role of PET/CT in the management of cervical cancer. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of endoscopy in the assessment and treatment of esophageal cancer. 
  • The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. 
  • The role of imaging in malignant pleural mesothelioma. 
  • The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. 
  • The role of lymphoscintigraphy in the management of the patient with breast cancer. 
  • The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. 
  • The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. 
  • The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. 
  • The role of surgery in stage B-2 malignancy. 
  • The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? 
  • The role of ultrasound-guided fine-needle aspiration of axillary nodes in the staging of breast cancer. 
  • The role of whole brain radiation therapy in the management of melanoma brain metastases. 
  • The side of the primary tumor affects overall survival in colon adenocarcinoma: an analysis of the national cancer database. 
  • The significance of distant metastases in breast cancer. 
  • The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. 
  • The small abnormal parathyroid gland is increasingly common and heralds operative complexity. 
  • The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). 
  • The state of prostate MRI in 2013. 
  • The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. 
  • The surgeon and adjuvant therapy for stage II colon cancer. 
  • The triangular intermuscular space as a site of lymph node metastasis in melanoma of the back. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • The use of electrocautery as the primary ablation modality for malignant and benign airway obstruction. 
  • The use of radiation therapy in localized high-grade soft tissue sarcoma and potential impact on survival. 
  • The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma. 
  • The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. 
  • Thin malignant melanomas of the head and neck. 
  • Thirty years of rectal cancer research: a brief history. 
  • Thoracic FDG PET: state of the art. 
  • Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. 
  • Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. 
  • Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. 
  • Thoracoscopic lobectomy: the gold standard for early-stage lung cancer? 
  • Thoracoscopic segmentectomy: technical considerations and outcomes. 
  • Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. 
  • Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. 
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 
  • Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer. 
  • Thymoma: benign appearance, malignant potential. 
  • Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer. 
  • Time-dose considerations in the treatment of anal cancer. 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. 
  • Timing of sentinel lymph node mapping after lymphoscintigraphy. 
  • Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI. 
  • Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. 
  • Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. 
  • Training for endobronchial ultrasound: methods for proper training in new bronchoscopic techniques. 
  • Transcript expression in endometrial cancers from Black and White patients. 
  • Transected thin melanoma: Implications for sentinel lymph node staging. 
  • Transoral robotic surgery using a carbon dioxide flexible laser for tumors of the upper aerodigestive tract. 
  • Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis. 
  • Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer. 
  • Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases. 
  • Treatment and Outcomes of Women With Large Locally Advanced Breast Cancer. 
  • Treatment of Lung Cancer in Medically Compromised Patients. 
  • Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin). 
  • Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. 
  • Treatment of uterine leiomyosarcoma. 
  • Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. 
  • Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. 
  • Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review. 
  • Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. 
  • Treatment-related toxicity and supportive care in metastatic colorectal cancer. 
  • Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. 
  • Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Trends in breast cancer stage and mortality in Michigan (1992-2009) by race, socioeconomic status, and area healthcare resources. 
  • Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. 
  • Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality. 
  • Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. 
  • Tumor Size, Histology, and Survival After Stereotactic Ablative Radiotherapy and Sublobar Resection in Node-negative Non-small Cell Lung Cancer. 
  • Tumor acquisition for biomarker research in lung cancer. 
  • Tumor characteristics in African American and white women. 
  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. 
  • Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. 
  • Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. 
  • Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. 
  • Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. 
  • Tumor proliferation in rectal cancer following preoperative irradiation. 
  • Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. 
  • Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. 
  • Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. 
  • Tyrosine kinase inhibitors in renal cell carcinoma. 
  • Ultrasound: the pulmonologist's new best friend. 
  • Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. 
  • Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. 
  • Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer. 
  • Unraveling the molecular nature of melanin changes in metastatic cancer 
  • Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. 
  • Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. 
  • Update in non-small cell lung cancer. 
  • Update on Surgical Management of Small Bowel Neuroendocrine Tumors. 
  • Update on pediatric testicular germ cell tumors. 
  • Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the AJR Special Series on Cancer Staging. 
  • Update on transrectal ultrasound-guided needle biopsy of the prostate. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updates in advanced prostate cancer 2018. 
  • Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. 
  • Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. 
  • Use and Outcomes of Minimally Invasive Lobectomy for Stage I Non-Small Cell Lung Cancer in the National Cancer Data Base. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Use of radiation and/or hyperthermia for treatment of mast cell tumors and lymphosarcoma in dogs. 
  • Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. 
  • Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. 
  • Uterine Neoplasms. Clinical Practice Guidelines in Oncology. 
  • Utility of LHRH antagonists for advanced prostate cancer. 
  • Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. 
  • Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma. 
  • Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. 
  • Utility scores and treatment preferences for clinical early-stage cervical cancer. 
  • Utilization Trends and Volume-outcomes Relationship of Endoscopic Resection for Early Stage Esophageal Cancer. 
  • Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. 
  • Utilization of Indocyanine Green to Aid in Identifying Sentinel Lymph Nodes in Merkel Cell Cancer. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. 
  • VATS and Minimally Invasive Resection in Early-Stage NSCLC. 
  • Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial. 
  • Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. 
  • Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. 
  • Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. 
  • Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. 
  • Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters in Predicting Prognosis for Patients With Cervical Cancer. 
  • Value of PET/CT in the management of liver metastases, part 1. 
  • Value of PET/CT in the management of primary hepatobiliary tumors, part 2. 
  • Value of intraoperative pleural lavage in staging non-small cell lung cancer. 
  • Value of magnetic resonance imaging for nodal staging in patients with head and neck squamous cell carcinoma: a meta-analysis. 
  • Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. 
  • Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. 
  • Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival. 
  • Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. 
  • Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. 
  • Vitamin D receptor polymorphisms and prostate cancer. 
  • Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. 
  • Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck. 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy. 
  • What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. 
  • What's new in neoadjuvant therapy for breast cancer? 
  • Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. 
  • Yes or no to local therapy for oligometastatic prostate cancer? 
  • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 
  • Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • [Bilateral breast cancer after Hodgkin disease. Clinical and pathological characteristics and therapeutic possibilities: an analysis of 13 cases]. 
  • [Diagnosis of early gastric marginal zone lymphoma (MALT lymphoma) in endoscopic biopsies. Report of a case that demonstrates the utility of immunohistochemistry and the molecular analysis.]. 
  • [Expectations and defeat in the treatment of epithelial cancer of the ovary]. 
  • [Femur reconstruction using combined autologous fibula transfer and humeral allograft]. 
  • [PCNA expression and AgNORs image analysis as factors in judging the prognosis of lung cancer]. 
  • [Primary chemotherapy in the treatment of breast cancer]. 
  • [The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer]. 
  • [Tumor regression as a prognostic factor in breast cancer]. 
  • miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. 
  • miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. 
  • p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. 
  • p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. 
  • p53 alterations in all stages of breast cancer. 
  • p53 overexpression in advanced-stage endometrial adenocarcinoma. 
  • p63 expression profile in normal and malignant prostate epithelial cells. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bitting, Rhonda L, Associate Professor of Medicine, Medicine, Medical Oncology
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Cohen, Seth Morris, Professor of Head and Neck Surgery & Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society